Based on expression analysis in patient-derived endometrial tumor tissues, we identify two potential targets – fibroblast activation protein (FAP) and melanoma-associated antigen A4 (MAGEA4) – for immunotherapy using an ex vivo vaccine setting. This evidence concerns the gene MAGEA4 and endometrium neoplasm.